The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.
One of the most pressing issues during the coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, is a potential emergence of viral escape variants that may render our current vaccines ineffective. This is especially concerning as the majority of the global population is still unvaccinated.
The interface between the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein and the receptor on host cells known as angiotensin-converting enzyme 2 (ACE2) mostly overlaps with binding sites for the most potent neutralizing antibodies we have, limiting the repertoire of likely mutations.
Consequently, mutations arising in the RBD may subtly change the interface between RBD and ACE2, but also between RBD and neutralizing antibodies. Furthermore, these mutations may interact (which is known as epistatic interactions) and subsequently increase the risk of vaccine escape.
And while the structures of the RBD-ACE2 interface in wild-type SARS-CoV-2 are quite similar to that of the RBD-NAb interface, just one mutation in the RBD can induce distinct shape changes in both interfaces and present with an additive effect.
A research group led by Dr. Nash D. Rochman from the National Center for Biotechnology Information, National Library of Medicine in Bethesda (United States) used unique protein structure modeling in order to study the potential of escape mutations.
Predicting the effects of mutations
In short, this study used an expensive computational approach to predict the effects of all single mutants at the RBD-NAb and RBD-ACE2 interfaces for the wild type SARS-CoV-2, but also its Gamma variant and Delta variant on receptor and antibody binding.
An ensemble of 50 native conformations per complex has been approximated with the use of standard Rosetta protocols. More specifically, after charting the wild-type SARS-CoV-2 RBD landscape, the researchers aimed to discern the most prominent combinations of RBD mutations that were in circulation over the course of the COVID-19 pandemic.
Moreover, the positive cost of the increase and the negative cost of the decrease in the ACE2 or neutralizing antibody binding affinity relative to the wild-type virus has been assessed in order to see whether it provides a selective advantage.
Escape mutations less likely for Delta variant
The results of this study imply that the emergence of escape mutants is less likely for the SARS-CoV-2 Delta variant in comparison to the wild type strain and moderately more likely for the Gamma variant in comparison to the wild type strain as well.
More specifically, many mutations were found in six sites for the wild type SARS-CoV-2, arguably with the ability to substantially destabilize the complex of neutralizing antibodies and RBD relative to the RBD-ACE2 complex – posing, in turn, a risk of vaccine escape.
“Overall, little epistasis at the RBD interface was detected, with additive effects on the binding affinities observed for most pairs of mutations”, emphasize study authors in this bioRxiv paper.
Hence, the detected non-additive trends in the Delta variant weakly stabilize the interaction of the RBD with the neutralizing antibodies relative to the interaction with ACE2; conversely, epistasis is predicted to destabilize interaction more substantially with the neutralizing antibodies relative to ACE2 in the Gamma variant.
A view into the vaccine-escape landscape
The authors conclude that the small set of escape-enhancing mutations that have been already established for the wild-type SARS-CoV-2 strain likely include the majority of all possible mutations with this effect, which is a rather encouraging finding.
“The modest ensemble of mutations relative to the wild type that are currently known to reduce vaccine efficacy is likely to comprise the majority of all possible escape mutations for future variants,” say study authors.
Hence, this work opens the door for a cheap and rapid view into the vaccine-escape landscape for any emerging variant of concern; however, further studies are needed in order to increase the predictive power of such research endeavors.
bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
- Rochman, N.D. et al. (2021). Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape. bioRxiv. https://doi.org/10.1101/2021.08.30.458225, https://www.biorxiv.org/content/10.1101/2021.08.30.458225v1
Posted in: Medical Research News | Disease/Infection News
Tags: ACE2, Angiotensin, Angiotensin-Converting Enzyme 2, Antibodies, Antibody, binding affinity, Biotechnology, Coronavirus, Coronavirus Disease COVID-19, Efficacy, Enzyme, Glycoprotein, Medicine, Mutation, Pandemic, Protein, Receptor, Research, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, Vaccine, Virus
Dr. Tomislav Meštrović
Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university – University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.
Source: Read Full Article